Targeted Lapatinib Anti-Her2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem
doi 10.20517/cdr.2019.92
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2020
Authors
Publisher
OAE Publishing Inc.